AbbVie Inc (ABBV)vsiRhythm Technologies Inc (IRTC)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
IRTC
iRhythm Technologies Inc
$111.43
-1.28%
HEALTHCARE · Cap: $4.03B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 7701% more annual revenue ($64.39B vs $825.34M). ABBV leads profitability with a 9.8% profit margin vs -1.7%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
IRTC
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for IRTC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 20.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 19.8x book value
0.0% earnings growth
ROE of -17.2% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : IRTC
The strongest argument for IRTC centers on Revenue Growth. Revenue growth of 20.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : IRTC
The primary concerns for IRTC are Price/Book, EPS Growth, Return on Equity. Debt-to-equity of 3.91 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while IRTC is a growth play — different risk/reward profiles.
IRTC carries more volatility with a beta of 1.32 — expect wider price swings.
IRTC is growing revenue faster at 20.1% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 32/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
iRhythm Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?